These findings suggest that a combination of MOS, TPL2 or MEK inhibitor and dasatinib may be a useful strategy for the treatment of BCR::ABL1‐independent dasatinib‐resistant CML. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.